Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV: Everolimus and Prednisone in Metastatic Renal Cell Cancer
NCT02479490Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2015
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, prednisone in metastatic renal cell carcinoma (mRCC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2015; status: terminated.
02
Drugs
everolimusprednisone
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02479490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479490.